Thursday's unveiling of regular ASCO abstract yielded a few initial winners and losers.

Four deaths cast doubt on J&J’s multi-pronged KLK2 push.

Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.

Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.

Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.

Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.

Tango cans TNG348 while Roche’s KSQ-4279 looks virtually inactive.

SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.